FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Platelet topics
Growth Factor
Fibroblast
Nanoparticle
Autologous
Leukocytes
Circulation
Transforming Growth Factor
Therapeutical
Platelet Derived Growth Factor
Bone Morphogenetic Protein
Endothelial
Recombinant
Stem Cells
Respiratory System
Dispensing System

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Platelet patents



      
           
This page is updated frequently with new Platelet-related patent applications. Subscribe to the Platelet RSS feed to automatically get the update: related Platelet RSS feeds. RSS updates for this page: Platelet RSS RSS


Date/App# patent app List of recent Platelet-related patents
07/02/15
20150185214
 Methods and kits for measuring von willebrand factor patent thumbnailnew patent Methods and kits for measuring von willebrand factor
Methods and kits for measuring levels of von willebrand factor function in a sample without using a platelet aggregation agonist, such as ristocetin, comprising recombinant glycoprotein ibα having a combination of g233v, d235y and m239v mutations and an agent to detect a complex between the recombinant glycoprotein ibα and von willebrand factor.. .
07/02/15
20150185210
 Platelet measurement reagent, platelet measurement reagent kit, and platelet measurement method patent thumbnailnew patent Platelet measurement reagent, platelet measurement reagent kit, and platelet measurement method
A reagent for measuring platelets comprising nile blue hydrogensulfate, or nile blue and an acid, a reagent kit for measuring platelets comprising the reagent for measuring platelets, and a method for measuring platelets using the reagent or reagent kit.. .
07/02/15
20150183995
 Pearlescent pigments coated with mixed inorganic/organic layers and  the production thereof patent thumbnailnew patent Pearlescent pigments coated with mixed inorganic/organic layers and the production thereof
The invention relates to platelet-shaped pearlescent pigments that are coated with at least one mixed inorganic/organic layer for improving their application properties, and of these, particularly their mechanical properties, and to methods for the production thereof and to the use thereof. The said mixed inorganic/organic layer comprises at least one at least partially crosslinked inorganic metal-oxide component and an organic component.
06/25/15
20150180073
 Ion-conducting membrane patent thumbnailIon-conducting membrane
An ion-conducting membrane includes: (i) a first ion-conducting layer including one or more first ion-conducting polymers; and (ii) a barrier layer including graphene-based platelets.. .
Johnson Matthey Fuel Cells Limited
06/25/15
20150174712
 Graphene nanoplatelet metal matrix patent thumbnailGraphene nanoplatelet metal matrix
A metal matrix composite is disclosed that includes graphene nanoplatelets dispersed in a metal matrix. The composite provides for improved thermal conductivity.
The Boeing Company
06/25/15
20150174591
 Centrifuge patent thumbnailCentrifuge
Centrifuges are useful to, among other things, remove red blood cells from whole blood and retain platelets and other factors in a reduced volume of plasma. platelet rich plasma (prp) and or platelet poor plasma (ppp) can be obtained rapidly and is ready for immediate injection into the host.
Kensey Nash Corporation
06/25/15
20150174313
 Blood component separation device patent thumbnailBlood component separation device
The object of the invention is to provide a blood separation device that can reduce the total time for drawing blood to obtain high-concentration platelet liquid, thereby reducing the binding time of the blood donor. The device includes a temporary storage bag (y2) (also serves as a buffy coat bag) which is a whole blood bag for storing whole blood drawn from a blood donor.
Terumo Kabushiki Kaisha
06/25/15
20150174221
 Systems, compositions, and methods for transplantation patent thumbnailSystems, compositions, and methods for transplantation
Systems and methods for purification and concentration of autologous alpha-2-macroglobulin (a2m) from whole blood are provided. Also provided are diagnostic methods for identifying sites in the synovial joints, spine, tendons or ligaments for treatment of pain, degeneration, or inflammation with autologous a2m.
Cytonics Corporation
06/25/15
20150174171
 Compositions and methods for the treatment and alleviation of bone and cartilage diseases or injuries and hair loss patent thumbnailCompositions and methods for the treatment and alleviation of bone and cartilage diseases or injuries and hair loss
The present invention provides pharmaceutical compositions, and methods of preparation and use for the treatment, prevention or alleviation of bone and cartilage diseases or injuries and hair loss. The present invention discloses a method and a pharmaceutical composition comprising mesenchymal stem cells, platelets, activating factors and scaffolding materials for the treatment, prevention, or alleviation of bone diseases, bone injuries or hair loss, and a method and a pharmaceutical composition further comprising dexamethasone for the treatment, prevention, or alleviation of cartilage diseases or injuries..
06/25/15
20150174170
 Compositions and methods for the treatment and alleviation of bone and cartilage diseases or injuries and hair loss patent thumbnailCompositions and methods for the treatment and alleviation of bone and cartilage diseases or injuries and hair loss
The present invention provides pharmaceutical compositions, and methods of preparation and use for the treatment, prevention or alleviation of bone and cartilage diseases or injuries and hair loss. The present invention discloses a method and a pharmaceutical composition comprising mesenchymal stem cells, platelets, activating factors and scaffolding materials for the treatment, prevention, or alleviation of bone diseases, bone injuries or hair loss, and a method and a pharmaceutical composition further comprising dexamethasone for the treatment, prevention, or alleviation of cartilage diseases or injuries..
06/18/15
20150166760

Metal effect pigments comprising a mixed inorganic/organic layer, the production of such metal effect pigments, and use thereof


The invention relates to metallic effect pigments with coating, comprising a platelet-shaped substrate, where the coating comprises at least one hybrid inorganic/organic layer, the hybrid layer having at least partly an inorganic network that has one or more inorganic oxide components, and having at least one organic component, the organic component being at least partly an organic oligomer and/or polymer which is covalently bonded at least partly to the inorganic network via one or more organic network formers. The invention further relates to a method of producing these metallic effect pigments, and to their use..
Eckart Gmbh
06/18/15
20150164956

Muscle-derived cells (mdcs) for treating muscle- or bone-related injury or dysfunction


The present invention provides muscle-derived cells, preferably myoblasts and muscle-derived stem cells, genetically engineered to contain and express one or more heterologous genes or functional segments of such genes, for delivery of the encoded gene products at or near sites of musculoskeletal, bone, ligament, meniscus, cartilage or genitourinary disease, injury, defect, or dysfunction. Ex vivo myoblast mediated gene delivery of human inducible nitric oxide synthase, and the resulting production of nitric oxide at and around the site of injury, are particularly provided by the invention as a treatment for lower genitourinary tract dysfunctions.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education
06/11/15
20150160214

Quantitation of cellular adhesion dynamics across immobilized receptors under rheological shear flow


The present invention includes an apparatus and methods for measuring cell or platelet adhesion comprising: a rheological shear flow surface coated with an agent that provides cell or platelet adhesion; a detector to track the transit of cells or platelets on the surface under shear flow; and a processor that calculates both a pause time and a roll time of platelets, wherein the processor determines a median and a mean pause time and a median and a mean roll time of cells or platelets and compares them to cells or platelets having at least one of: no cell adhesion dysfunction, a mild adhesion dysfunction, or a severe adhesion dysfunction, between a cell surface adhesion molecule on the cell or platelet and the agent, wherein the processor provides a real-time, quantitative measurement of a dynamic range of cell or platelet adhesion.. .
Mayo Foundation For Medical Education And Research
06/11/15
20150160213

Compositions and methods for assaying platelet reactivity and treatment selection


Compositions and methods are provided for determining platelet reactivity where the levels of fcγriia on the surface of platelets is measured and if the levels of fcγriia are greater than a reference value, the platelets have enhanced reactivity.. .
The University Of Vermont And State Agriculture College
06/04/15
20150155340

Dual-mode pixels including emissive and reflective devices, and dual-mode display using the pixels


Provided is a dual-mode display including a substrate and a plurality of sub-pixels on the substrate, in which each sub-pixel includes an emissive device, a color selection reflector disposed on one side of the emissive device, and an optical shutter disposed on another side of the emissive device, wherein the emissive device includes a cathode and an anode, and the cathode and the anode include a carbon-based material including graphene sheets, graphene flakes, and graphene platelets, and a binary or ternary transparent conductive oxide including indium oxide, tin oxide, and zinc oxide.. .
Electronics And Telecommunications Research Institute
06/04/15
20150152314

Cement composition comprising nano-platelets


A method of cementing a subterranean formation includes providing a cement composition comprising cementitious material, aqueous base fluid, graphene nano-platelets, and a dispersant; introducing the cement composition into a subterranean formation; and allowing the cement composition to set in the subterranean formation. Upon setting, the cement has at least one of enhanced compressive and tensile strength; reduced permeability; restricted penetration of carbon dioxide; and combinations thereof relative to an equivalent cement without graphene nano-platelets.
Halliburton Energy Services, Inc.
06/04/15
20150152111

Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition


The invention provides new triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation.. .
Astrazeneca Uk Limited
06/04/15
20150150942

Methods for extracting platelets and compositions obtained therefrom


This invention provides methods for extracting platelets, compositions obtained therefore, and methods for using the same.. .
The Regents Of The University Of Colorado, A Body Corporate
05/28/15
20150148901

Apparatus and breast reconstruction and augmentation using an autologous platelet-rich fibrin matrix


Described herein are systems and methods for soft tissue reconstruction and augmentation using a platelet-rich fibrin matrix. In one embodiment the system of the present invention includes a blood collection apparatus capable of drawing blood from a patient, a matrix preparation container configured to hold a patient's blood while the blood is separated and coagulated to form a platelet-rich fibrin matrix therein, and a matrix delivery device configured to receive the matrix preparation container therein and compress and force the platelet-rich fibrin matrix out of the matrix preparation container and into the patient.
05/28/15
20150148385

Pharmaceutical composition containing a compound having a thrombopoietin receptor agonistic activity


“when the platelet count has increased by a certain amount and reached to a sufficient level of the platelet count during administration of a pharmaceutical composition containing a compound having a thrombopoietin receptor agonistic activity, administration of the pharmaceutical composition is discontinued thereafter”.. .
05/28/15
20150147300

Methods of mediating macrophage phenotypes


Methods of inducing a polarization of macrophages. The method includes obtaining a blood fraction, fractionating the blood fraction to produce a blood fraction, and contacting the blood fraction with a source of macrophages.
Biomet Biologics, Llc
05/28/15
20150147228

Permanent magnet, and motor and generator using the same


In one embodiment, a permanent magnet has a composition represented by a composition formula: rpfeqmrcusco100-p-q-r-s, where r is a rare earth element, m is at least one element selected from zr, ti, and hf, p is 8.0 atomic % or more and 13.5 atomic % or less, q is 25 atomic % or more and 40 atomic % or less, r is 0.88 atomic % or more and 7.2 atomic % or less, and s is 3.5 atomic % or more and 13.5 atomic % or less, and a metallic structure including a cell phase having a th2zn17 crystal phase, a cell wall phase, and a platelet phase existing along a c plane of the th2zn17 crystal phase. An average thickness of the platelet phase is in a range of from 2.5 nm to 20 nm..
Kabushiki Kaisha Toshiba
05/21/15
20150141477

Pyrazole derivatives and their use as lpar5 antagonists


The present invention relates to compounds of the formula (i), wherein the residues r1 to r5, v, g and m have the meanings indicated in the claims. The compounds of the formula (i) are valuable pharmacologically active compounds for use in the treatment of diverse disorders, for example cardiovascular disorders like thromboembolic diseases or restenoses.
Sanofi
05/21/15
20150141471

Pyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formation


The present invention relates to compounds of the formula (i), wherein the residues r1 to r6, v, g and m have the meanings indicated in the claims. The compounds of the formula i are valuable pharmacologically active compounds for use in the treatment of diverse disorders, for example cardiovascular disorders like thromboembolic diseases or restenoses.
Sanofi
05/21/15
20150141332

Methods for diagnosing osteoarthritis


Methods for managing osteoarthritis, in a human or other mammalian subject, comprising the measurement of certain cytokines and growth factors in a tissue sample of a subject, including one or more of platelet-derived growth factor ab (pdgf-ab), platelet-derived growth factor bb (pdgf-bb), and epidermal growth factor (egf). Tissue samples may be whole blood, blood fractions, urine, saliva, and synovial fluid.
Biomet Biologics, Llc
05/21/15
20150140120

Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics


Materials and methods are provided for producing and using aptamers useful as oncology therapeutics capable of binding to pdgf, pdgf isoforms, pdgf receptor, vegf, and vegf receptor or any combination thereof with great affinity and specificity. The compositions of the present invention are particularly useful in solid tumor therapy and can be used one or in combination with known cytotoxic agents for the treatment of solid tumors.
Archemix Llc
05/14/15
20150135344

Methods of modulating thrombocytopenia and modified transgenic pigs


The application provides methods of modulating platelet uptake by liver sinusoidal endothelial cells and of modulating thrombocytopenia. Transgenic pigs modified to bind fewer platelets are provided..
05/14/15
20150133446

Imidazothiadiazole derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation


The present invention provides imidazothiadiazole compounds of formula (i) wherein a, b, d, rx, r1, r2, r3, x1, x2 and s are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments..
05/14/15
20150132261

Treatment of thrombocytopenia using orally administered interferon


An interferon composition is provided for enhancing the platelet count, reducing the recurrence rate of hepatitis, and/or improving the social function of hepatitis patients. The method comprises administering a low dose of ifn (about 5 iu to about 2500 iu of ifn-alpha) to a patient in need thereof.
05/14/15
20150128935

Inhalation systems, breathing apparatuses, and methods


Examples of the invention include inhalation systems, breathing apparatuses, and methods for administering a solution by inhalation to a patient. Example breathing apparatuses described herein may be configured to minimize loss of the solution to the environment.
05/07/15
20150126527

Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto


The present invention relates to amide derivatives of formula (xiiia) and pharmaceutical compositions thereof that modulate the activity of the pgi2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (pah); idiopathic pah; familial pah; pah associated with a collagen vascular disease, a congenital heart disease, portal hypertension, hiv infection, ingestion of a drug or toxin, hereditary hemorrhagic telangiectasia, splenectomy, pulmonary veno-occlusive disease (pvod) or pulmonary capillary hemangiomatosis (pch); pah with significant venous or capillary involvement; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack, angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (sle); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (copd)..
05/07/15
20150125436

Process, tube and device for the preparation of wound healant composition


The present invention is related to the field of tissue regeneration. It concerns more particularly new processes, tubes and devices for thrombin, platelet concentrate and wound healant preparations, alone or in combination with cell extracts, cell compositions and uses thereof..
05/07/15
20150125430

Compositions and methods for inducing thrombopoiesis


Methods of inducing thrombopoiesis and/or treating thrombocytopenia in a subject are provided. Accordingly there is provided a method comprising contacting stem cells with a differentiation potential towards platelets or hematopoietic progenitor cells derived therefrom with livin, thereby inducing thrombopoiesis.
Hadasit Medical Research Services And Development Ltd.
05/07/15
20150122713

Prp obtaining device


A platelet rich plasma (prp) obtaining device includes a container attached to a receptacle for allowing a material in the receptacle to flow into the container, a piston engaged in the receptacle for forcing the material to partially flow into the container, a housing slidably engaged in the container and having a space and having a tube extended in the housing, the tube includes a bore communicating with a compartment of the container, but offset from the space of the housing, and a check valve is attached to the housing for limiting the material to flow only from the container to the housing, and for preventing the material from flowing backward from the housing into the container.. .
Yung Kang Medical Device & Technologic Co., Ltd.
04/30/15
20150119495

Preparation of rubber composition containing graphite platelets and tire with component


Preparation of a rubber composition containing a dispersion of aligned exfoliated graphite platelets. Such rubber composition is prepared by a method comprised of a sequential combination of concentrated solvent or dry masterbatching of elastomer and exfoliated graphite platelets, followed by blending the masterbatch (after removing the solvent from the solvent based masterbatch) with additional elastomer(s) and then followed by processing the resulting rubber composition to align the dispersed exfoliated graphite platelets in a substantially parallel relation to each other.
The Goodyear Tire & Rubber Company
04/30/15
20150119390

Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation


The present invention provides imidazothiadiazole compounds of formula (i); wherein w, y, r0, r2, r4, ra, rb, x1, x2, x3 and x4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders..
Universite De Monteal
04/30/15
20150118210

Composition for enhancing cell engraftment and homing properties containing prp as active ingredient


The present invention provides a composition for enhancing cell engraftment and homing properties, containing platelet-rich plasma (prp) as an active ingredient. The present invention provides a method for improving cell engraftment and homing properties, comprising the step of treating in vitro isolated cells with a composition containing prp as an active ingredient.
Snu R&db Foundation
04/30/15
20150118109

Component preparation system


Disclosed herein are centrifuge-free self-contained systems for aseptically separating components of whole blood comprising at least one cassette for receiving whole blood; at least one red blood cell exclusion filter; at least one leukocyte reduction filters; at least one platelet exclusion filter; a plurality of product cassettes; and optionally a plurality of pumps and valves; and wherein the filters, pumps, valves, and cassettes are fluidly connected by tubing and the system does not include a centrifuge. Also disclosed are methods for obtaining blood components using the system..
New York Blood Center, Inc.
04/23/15
20150111889

Benzo[1,3]dioxine derivatives and their use as lpar5 antagonists


The present invention relates to compounds of the formula (i), wherein the residues a, r1 to r5, z1 and z2 have the meanings indicated in the claims. The compounds of the formula (i) are valuable pharmacologically active compounds for use in the treatment of diverse disorders, for example cardiovascular disorders like thromboembolic diseases or restenoses.
Sanofi
04/23/15
20150111777

Biomarker for early neurodegeneration detection


The present invention relates to compositions, methods, and kits that can be used to assess neurodegeneration associated diseases and conditions in a subject by detecting the level of tdp-43 protein in platelets. The compositions, methods, and kits are suitable for neurodegeneration associated disease diagnosis, prognosis and treatment evaluation..
Kansas City University Of Medicine And Biosciences
04/16/15
20150105338

Therapeutic compositions comprising phenolic acids for treating conditions related to inappropriate platelet aggregation


The invention provides compositions comprising a therapeutically effective amount of a compound of general formula (i): wherein r1, r2 and r3 may be independently selected from h, oh and ome; wherein x is c1 or c2 and wherein for c2 each carbon is linked by a single or multiple bond (preferably a double bond) and is substituted with one or more h or oh, for use as a medicament for treating or preventing the development of medical conditions characterised by inappropriate platelet aggregation. The compositions of the invention may be used to maintain heart health by reducing platelet aggregation; benefit the circulation; and/or normalize or otherwise benefit blood flow..
Provexis Natural Products Limited
04/16/15
20150104436

Application and pharmaceutical composition of preactivated and disaggregated shape-changed platelets


Preactivated and disaggregated shape-changed platelets, fixed shape-changed platelets, and a pharmaceutical composition thereof are used for treating acute and emergent inflammatory disease in a dosage of 1×106 to 1×108. Activated platelets release and transfer adhesion factors to the surface of platelet cells, and trap stromal vascularity inflammatory cells from inflammated and damaged place, and the stromal vascularity inflammatory cells are eliminated through the circulatory system to alleviate inflammation.
Chang Gung Medical Foundation, Linkou Branch
04/16/15
20150101995

Device and extracting high-concentration plasma from whole blood


Disclosed are a device and method of extracting high-concentration plasma from whole blood. The device comprises: a first syringe; a centrifugation tube that is connected to the first syringe in order to centrifuge whole blood received in the first syringe; a cap that is connected to the first syringe in order to re-centrifuge plasma collected in the first syringe by centrifugation of the whole blood; and a membrane filter comprising: a body that is cylindrical in shape and has a pair of spaced inlets to which the first syringe and a second syringe are to be respectively connected; a hollow membrane included in the body; and a first space formed between the body and the membrane and serving to collect components that passed through the membrane.
04/09/15
20150099716

Maintenance of platelet inhibition during antiplatelet therapy


A method for reducing or maintaining platelet inhibition in a patient by administering cangrelor prior to an invasive procedure is described. The method of this invention can be used for patients in need of antiplatelet therapy or at risk of thrombosis.
The Medicines Company
04/09/15
20150099298

Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof


The present invention relates to antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.. .
Bayer Pharma Aktiengesellschaft
04/09/15
20150098939

Novel antagonist antibodies and their fab fragments against gpvi and uses thereof


The present invention discloses novel antibodies that specifically bind to the human platelet membrane protein glycoprotein vi (gpvi) and their monovalent fragments or derivatives. The antibodies of the invention are antibodies from hybridoma clone 390 and fragment antibodies thereof able to induce a gpvi depletion phenotype.
Sanofi
04/02/15
20150094298

Inhibitors of protein kinases


The present invention is directed to compounds of formula i-ii and pharmaceutically acceptable tautomers, salts, or stereoisomers thereof which are inhibitors of syk and/or jak kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk and/or jak kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk and/or jak kinase activity, such as undesired thrombosis and non hodgkin's lymphoma..
Portola Pharmaceuticals, Inc.
04/02/15
20150094297

Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation


The present invention provides thiazole compounds of formula i wherein w, y, r0, r2, r4, r5, r6, r7, x1, x2, x3 and x4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders..
Universite De Montreal
04/02/15
20150093770

Method and device for the determination of platelet function under flow conditions


The invention lies in the area of platelet function diagnostics and relates to a method for the determination of platelet function under flow conditions as well as a device for the implementation of this method. The method is particularly suitable for the determination of the effect of clopidogrel and of other p2y(12) antagonists with antithrombotic activity as well as the determination of p2y(1) antagonists with antithrombotic activity..
Siemens Healthcare Diagnostics Products Gmbh
04/02/15
20150093543

Blood compatible surfaces


The disclosure features blood compatible articles and methods of making the articles. The methods include providing a substrate and forming a rough surface on the substrate.
Teijin Limitied
04/02/15
20150093390

Humanized and chimeric anti-factor bb antibodies and uses thereof


A method of inhibiting complement activation mediated by bb inhibitors in a subject includes administering a bb inhibitor to the subject to inhibit at least one of bb binding to factors b and properdin, inhibit c3 cleavage, inhibit the activation of neutrophils, monocytes, platelets, and endothelium; or inhibit the formation of c3a, c5a, and mac.. .
Novelmed Theraperutics, Inc.
03/26/15
20150083973

Systems, devices, and/or methods for solar cells comprising a light amplification element


Certain exemplary embodiments can provide a method, which can comprise fabricating a system. The system can comprise a light amplification element and a charge transport element.
K Tube Technology Llc
03/26/15
20150083355

Fibrous pulp and use thereof in a composite


A composition comprises (i) an elastomer, (ii) from 1 to 5 volume % of fibrous pulp, the pulp having a specific surface area of from 7 to 11 sq.m./g and the fiber having a fiber length of from 0.5 to 1.1 mm, a tensile modulus of from 2.5 to 130 gpa, and a tensile strength of from 1 to 3 gpa, and (iii) from 5 to 14 volume % of yield-strain promoter in the form of fibers, needles, powder or platelets, wherein the composition has a yield strain of at least 70%, an elongation at break of at least 200%, and a yield stress of at least 4 mpa.. .
E I Du Pont De Nemours And Company
03/19/15
20150080300

Growth factor concentrate and the use thereof


Provided herein are growth factor concentrates, cosmetic compositions and methods for cosmetic treatment. The growth factor concentrates comprise decapsulated growth factors derived from platelet rich plasma..
Bestop Group Holdings Limited
03/19/15
20150079194

Systems, compositions, and methods for transplantation and treating conditions


Systems and methods for purification and concentration of autologous alpha-2 macroglobulin (a2m) from whole blood and or recombinant a2m are provided. Also provided are methods of treating wounds with a2m.
Cytonics Corporation
03/19/15
20150079169

Controlled dosing of clopidogrel with gastric acid inhibition therapies


The present invention provides for novel formulations of clopidogrel in combination with proton pump inhibitors (ppi) and optionally with nsaids, for use as improved antiplatelet therapies in stroke and cardiovascular indications. The invention provides the delivery of clopidogrel in pulses or waves, such that the total dose is phased/spread out over time and, advantageously, combined with omeprazole in a way to minimize the conflicting actions these two drugs may have on each other.
Pozen Inc.
03/19/15
20150079153

Cell suspension and use thereof


The present invention provides for methods and devices suitable for producing a transplantable cellular suspension of living tissue suitable for promoting tissue regeneration in an epithelium-related procedure, as well as compositions produced therefrom. The cellular suspension can include viable and functioning cells at various stages of differentiation, including undifferentiated/progenitor cells and differentiated cells, as well as those in between.
Avita Medical Ltd.
03/19/15
20150079142

Devices and methods for preventing platelet activation


Methods for inhibiting a biomaterial-associated thrombotic event comprise reducing the number of platelets that bind to the biomaterial, or inhibiting platelet activation, by attaching cd47 or the ig domain thereof to the surface of the biomaterial. Methods of the present invention inhibit thrombi formation on or near a biomaterial that is on the surface of an implant, medical device, tube, or therapeutic delivery vehicle.
The Children's Hospital Of Philadelphia
03/19/15
20150079045

Nprcps, pfdncs and uses thereof


Identification of a group of novel particle termed “non-platelet rna-containing particles (nprcp)” provides novel compositions, downstream products and therapeutic tools. In addition a group of mixed nprcps were identified that contain rnas and proteins.


Popular terms: [SEARCH]

Platelet topics: Growth Factor, Fibroblast, Nanoparticle, Autologous, Leukocytes, Circulation, Transforming Growth Factor, Therapeutical, Platelet Derived Growth Factor, Bone Morphogenetic Protein, Endothelial, Recombinant, Stem Cells, Respiratory System, Dispensing System

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Platelet for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Platelet with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         





0.313

3385

2 - 1 - 73